About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

GlobalData recently reported that the GLP-1R market experienced significant growth ... Viking Therapeutics ($5.2bn), Structure Therapeutics ($1.8bn) and Altimmune ($642m) are small-cap to mid-cap ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

If you're one of the 13% of American adults who has taken a GLP-1 drug for weight loss, you may know that while fat seemingly ...

Maintaining muscle mass is crucial for health, and researchers have identified the protein BCL6 as vital for this. Studies ...

With the recent surge in popularity of weight loss drugs like Ozempic, altogether called GLP-1s, there has been renewed scientific interest in understanding how our bodies regulate muscle growth.